背景:强直性脊柱炎(AS)是一种慢性炎症性疾病,以引起疼痛而闻名,刚度,和减少在轴向骨架的流动性。阿达木单抗,肿瘤坏死因子(TNF)抑制剂,已成为AS的一种有前途的治疗选择。
方法:本系统综述涉及与AS治疗相关的随机对照试验的全面检索,在MEDLINE等主要数据库中进行,谷歌学者,和PubMed。搜索词包括强直性脊柱炎,阿达木单抗,甲氨蝶呤,其他非生物DMARDs,糖皮质激素,NSAIDs,和镇痛药.共有14项随机对照试验纳入了4,500名参与者。
结果:该综述的结果显示,与安慰剂相比,阿达木单抗表现出显著的优越性。它有效地减少了疾病活动,改善身体机能,并降低炎症标志物如C反应蛋白和红细胞沉降率。阿达木单抗表现出良好的安全性,与安慰剂观察到的不良事件相当。
结论:根据结果,阿达木单抗被认为是AS的有效治疗方法,展示其作为一线治疗选择的潜力。值得注意的是,与安慰剂相比,不良事件没有显著增加.然而,本结论强调需要延长随访时间的进一步研究,以确定阿达木单抗在AS治疗中的长期疗效和安全性.本系统综述提供了支持阿达木单抗在AS治疗中的应用的宝贵见解,并强调了对其长期影响进行持续研究以优化其在AS患者中的临床利用的重要性。
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory disease known for causing pain, stiffness, and reduced mobility in the axial skeleton. Adalimumab, a tumor necrosis factor (TNF) inhibitor, has emerged as a promising therapeutic option for AS.
METHODS: This systematic review involved a comprehensive search of randomized controlled trials related to AS treatment, conducted in major databases such as MEDLINE, Google Scholar, and PubMed. The search terms encompassed ankylosing spondylitis, adalimumab, methotrexate, other non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics. A total of 14 randomized controlled trials with 4,500 participants were included in the review.
RESULTS: The review\'s results revealed that adalimumab demonstrated notable superiority when compared to a placebo. It effectively reduced disease activity, improved physical function, and lowered inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. Adalimumab demonstrated a favorable safety profile, with adverse events comparable to those observed with placebo.
CONCLUSIONS: Based on the results, adalimumab is deemed an effective treatment for AS, showcasing its potential as a first-line therapeutic option. Notably, no significant increase in adverse events was observed compared to placebo. However, the conclusion emphasizes the need for further studies with extended follow-up durations to ascertain the long-term efficacy and safety of adalimumab in AS management. This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients.